Biologically active LIL proteins built with minimal chemical diversity

Erin N. Heim, Jez L. Marston, Ross S. Federman, Anne P. B. Edwards, Alexander G. Karabaghchak, Lisa M. Petti, Donald M. Engelman, and Daniel DiMaio

Department of Genetics, Yale School of Medicine, New Haven, CT 06520-8005; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520-8011; Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520-8024; Yale Cancer Center, New Haven, CT 06520-8028; and Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520-8040

Contributed by Donald M. Engelman, July 21, 2015 (sent for review April 15, 2015; reviewed by Alessandro Senes and Bill Sugden)

We have constructed 26-amino acid transmembrane proteins that specifically transform cells but consist of only two different amino acids. Most proteins are long polymers of amino acids with 20 or more chemically distinct side-chains. The artificial transmembrane proteins reported here are the simplest known proteins with specific biological activity, consisting solely of an initiating methionine followed by specific sequences of leucines and isoleucines, two hydrophobic amino acids that differ only by the position of a methyl group. We designate these proteins containing leucine (L) and isoleucine (I) as LIL proteins. These proteins functionally interact with the transmembrane domain of the platelet-derived growth factor β-receptor and specifically activate the receptor to transform cells. Complete mutagenesis of these proteins identified individual amino acids required for activity, and a protein consisting solely of leucines, except for a single isoleucine at a particular position, transformed cells. These surprisingly simple proteins define the minimal chemical diversity sufficient to construct proteins with specific biological activity and change our view of what can constitute an active protein in a cellular context.

Significance

Most proteins are long polymers of amino acids with 20 or more chemically distinct side-chains, whereas transmembrane domains are short membrane-spanning protein segments with mainly hydrophobic amino acids. Here, we have defined the minimal chemical diversity sufficient for a protein to display specific biological activity by isolating artificial 26-aa-long transmembrane proteins consisting of random sequences of only two hydrophobic amino acids, leucine and isoleucine. A small fraction of proteins with this composition interact with the transmembrane domain of a growth factor receptor to specifically activate the receptor, resulting in growth transformation. These findings change our view of what can constitute an active protein and have important implications for protein evolution, protein engineering, and synthetic biology.


Reviews: A.S., University of Wisconsin–Madison; and B.S., University of Wisconsin.

The authors declare no conflict of interest.

1J.L.M. and R.S.F. contributed equally to this work.
2To whom correspondence may be addressed. Email: daniel.dimaio@yale.edu or donald.engelman@yale.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1514230112/-/DCSupplemental.
We have developed genetic methods to select short biologically active transmembrane proteins modeled on the E5 protein from libraries expressing many thousands of artificial proteins with randomized hydrophobic segments (named transmembrane protein aptamers or “traptamers”) (22–25). Because of the relative simplicity of transmembrane domains, we reasoned that this approach could be used to define the minimal chemical complexity sufficient to construct biologically active proteins. Here, we isolate short transmembrane oncoproteins that are the simplest proteins ever described with specific biological activity. These proteins change our understanding of the chemical diversity required for protein function.

**Results**

To isolate ultrasimple oncoproteins, we constructed a retroviral library (designated UDv6) expressing traptamers in which a methionine initiation codon was followed by 25 codons encoding equimolar leucine and isoleucine in random order (Fig. 1A and B).

![Fig. 1.](image)

**Fig. 1.** Proteins composed of only leucine and isoleucine transform cells. (A) Isoleucine and leucine side-chains differ in the position of a methyl group. Valine is identical to isoleucine except for the absence of a terminal methyl group. (B) Sequences of the UDv6 library and the active traptamers. The first line shows the design of the library, where M represents methionine and X represents positions randomized to be equimolar leucine (L) and isoleucine (I). The other lines show the sequences of the 11 active traptamers. (C) Scheme to isolate traptamers with transforming activity. C127 mouse fibroblasts were infected with a retrovirus library expressing traptamers (the different colored cylinders represent different traptamer sequences) and incubated at confluence for 3 wk. The red traptamer induces transformation (indicated by the dark blue cells) and focus formation. Genes encoding the traptamers were cloned from genomic DNA isolated from cell expanded from individual transformed foci. Traptamer activity was validated by reintroduction into naïve C127 cells. (D) C127 cells were infected with high-titer stocks of empty vector (MSCV), or MSCV expressing BPV E5, polyL25, or traptamer LI-11. Photomicrographs were taken at 100× magnification 10 d later. Transformed cells are refractile and irregularly pile on each other after loss of contact inhibition. (E) C127 cells were infected with low-titer stocks of the viruses expressing traptamers listed in B, and foci of transformed cells were counted 3 wk later. Focus-forming activity (number of foci formed normalized to viral titer) of traptamers is shown relative to E5 activity (set at 100%). V, cells infected with empty MSCV vector. The results show the average of three independent experiments with SE.
Fig. 2. Traptamers specifically bind and activate the PDGFβR. (A) Extracts prepared from C127 cells expressing MSCV vector (V), the E5 protein, or the indicated traptamer were immunoprecipitated with anti-PDGF receptor (PR) antibody and blotted for phosphotyrosine (PY, Upper) or PDGFβR (Lower). m, mature PDGFβR; p, precursor form of the receptor with immature carbohydrates activated by the E5 protein and some of the traptamers. (B) Extracts were prepared from human diploid fibroblasts that were untreated (MSCV), acutely treated with PDGF-DD (PDGF) or with a mixture of growth factors, or stably transformed by traptamer LI-5, LI-8, and LI-11. Phospho-RTK arrays were incubated with cell extracts, processed, and exposed to film for the same length of time. The spots representing PDGFβR are underlined in red on all arrays. EGF receptor, PDGFαR, and Axl are underlined in blue, green, and purple, respectively, on the array probed with the extract of control cells. The dark pairs of spots at the corners are standards. (C) BaF3 cells expressing the PDGFβR (PR), the erythropoietin receptor (EpoR) (Left), or the c-kit (Right) were infected with MSCV or MSCV expressing the indicated traptamer or v-sis (for PR cells) or treated with EPO (for EpoR cells) or stem cell factor (SCF, for c-kit cells). The number of live cells was counted 5 d after IL-3 removal. Each experiment was performed three times. Although the inherent variability of this assay precluded a rigorous statistical analysis, the same trends were observed in each experiment. The graphs show the results of a representative experiment. (D) BaF3 cells expressing the LXSN empty vector, the PDGFβR, a chimeric PDGFαR containing the transmembrane domain of the PDGFαR (βαβ), or a mutant PDGFβR were infected with MSCV or MSCV expressing v-sis, the E5 protein, or the indicated traptamer. The number of live cells was counted 5 d after IL-3 removal. The experiment was performed three times and the same trends were observed in each experiment. The graph shows the results of a representative experiment. (E) Detergent extracts were prepared from untransformed C127 cells harboring MSCV (V) or cells transformed by the indicated FLAG-tagged (+) or untagged (−) traptamer. Extracts were immunoprecipitated (IP) and immunoblotted (IB) with the indicated antibody. (F, Left) Detergent extracts were prepared from BaF3 cells expressing the PDGFβR and MSCV or the indicated FLAG-tagged traptamer. US2 and US16 are inactive unselected clones. Extracts were immunoprecipitated with anti-FLAG and immunoblotted with anti-PDGF receptor. Both panels were from the same exposure from the same gel; an irrelevant lane was removed. (Right) Detergent extracts were prepared from BaF3 cells expressing the PDGFβR or the βαβ chimeric receptor together with MSCV or FLAG-tagged LI-5 or LI-7. Extracts were immunoprecipitated with anti-FLAG and immunoblotted with anti-PDGF receptor.
The theoretical complexity of this library is \(2^{25} \approx 33.5\) million. For the experiments reported here, we pooled \(-5.5\) million bacterial colonies to generate the library, setting an upper limit on the number of independent sequences in the library. Normal C127 mouse fibroblasts were infected at low multiplicity with \(-160,000\) clones from the library, and rare foci of transformed cells were isolated and expanded into cell lines (Fig. 1C). Individual traptamer genes recovered from the DNA of these cells were tested for transforming activity. Eleven recovered traptamers, each with a different sequence (Fig. 1B), induced morphologic transformation in C127 cells and in human primary foreskin fibroblasts (HFFs) (Fig. 1D and Fig. S1). Several of these traptamers strongly induced focus formation in C127 cells (approximately 40 transformed foci per 1,000 infectious units, similar to the BPV E5 protein) (Fig. 1E), although we cannot normalize the transforming activities of the various traptamers to their expression because the abundance of these untagged proteins cannot be measured. In contrast, a clone consisting of methionine followed by 25 leucines (designated polyL25) did not induce transformation (Fig. 1D), nor did traptamers randomly chosen from the library without biological selection (Fig. S2). Codon-optimized versions of traptamers LI-7 and LI-11, which contained numerous nucleotide changes that did not affect the amino acid sequence, transformed cells, whereas introduction of a single translation stop codon abolished activity (Fig. S3). Thus, the encoded proteins and not the RNA structures are responsible for transformation.

We hypothesized that the active traptamers induced transformation by interacting with a cellular target protein and activating a mitogenic signaling cascade. To determine if these traptamers, like the E5 protein, activate the PDGFβR, lysates of transformed C127 cells were immunoprecipitated with anti-PDGFβR and immunoblotted with anti-phosphotyrosine antibody. As shown in Fig. 2A, Upper, basal tyrosine phosphorylation of the PDGFβR in untransformed cells was very low. In contrast, substantial tyrosine phosphorylation of the PDGFβR was detected in cells expressing the E5 protein or any of the active traptamers, indicating that the traptamers activate the PDGFβR. Like the E5 protein, some of the traptamers activated not only the mature form of the receptor, but also a rapidly migrating precursor form of the PDGFβR containing immature carbohydrates. This might result from the localization of different traptamers (and hence the activation) in different intracellular compartments.

To examine the specificity of the traptamers, we used phosho-RTK arrays to assess activation of numerous RTKs. Extracts were prepared from serum-starved HFFs, from HFFs acutely treated with PDGF-DD [which nominally activates only the PDGFβR (26)] or a mixture of growth factors, or from HFFs stably transformed by traptamer LI-5, LI-8, or LI-11. These extracts were incubated with nitrocellulose membranes containing duplicate spots of antibodies that captured 49 individual RTKs, after which the membranes were probed with an anti-phosphotyrosine antibody. The intensity of a spot corresponds to the extent of tyrosine phosphorylation of the target RTK. As shown in Fig. 2B, the PDGFβR, PDGF-α receptor (PDGFRα), EGF receptor, and Ad showed a low basal level of constitutive tyrosine phosphorylation in control cells. PDGF-DD caused a dramatic increase in tyrosine phosphorylation of the PDGFβR and lesser increases in several other RTKs, whereas treatment with the growth factor mixture resulted in tyrosine phosphorylation of many RTKs. Strikingly, for all three tested traptamers, the only significant difference compared with control cells was markedly increased tyrosine phosphorylation of the PDGFβR (Fig. 2B), demonstrating that the traptamers are highly specific in their ability to activate the PDGFβR. Indeed, in this assay the traptamers were more specific for the PDGFβR than was PDGF itself. Minor differences in the intensity of some faint spots in response to a given traptamer were not reproducible.

We used murine BaF3 cells to determine if traptamer activity required the PDGFβR. BaF3 cells lack endogenous PDGFβR and require IL-3 for growth, but become IL-3–independent if an exogenous growth factor receptor is expressed and activated (Fig. 2C) (27, 28). Cells expressing the PDGFβR alone or the traptamer alone grew poorly in the absence of IL-3. However, when PDGFβR was coexpressed with v-sis, the viral homolog of PDGF, or any of the four tested traptamers, the cells proliferated in the absence of IL-3 (Fig. 2C), demonstrating that the traptamers require PDGFβR for activity. We also tested the traptamers in BaF3 cells expressing a different RTK, c-kit, or a cytokine receptor, the erythropoietin receptor (EPOR). Both of these receptors conferred IL-3 independence when stimulated with their cognate ligands but did not confer IL-3 independence in response to the traptamers (Fig. 2C). Thus, the ability of the traptamers to confer growth factor independence was specific for the PDGFβR. We also used this system to map the domain of the PDGFβR required for productive interaction. We first analyzed BaF3 cells expressing a chimeric receptor in which the transmembrane domain of the PDGFβR was replaced with the transmembrane domain of the PDGFRα (Fig. 2D) (29, 30). Cells expressing βαβ showed that tagged traptamers require the PDGFβR transmembrane domain for activity and that activity is inhibited by single amino acid substitutions in this segment of the receptor.

Next we wished to investigate whether the traptamers interacted with the PDGFβR, but the very hydrophobic nature of the traptamers complicates biophysical analysis, which traditionally has been used to study the interaction of natural and artificial transmembrane domains with far greater chemical diversity (10, 31, 32). Therefore, we used communoprecipitation to determine if the traptamers were present in a stable complex with the PDGFβR in transformed cells. We first added a FLAG epitope tag to the N terminus of traptamers LI-5, LI-7, and LI-11. Addition of the FLAG-tag caused no more than a ~50% increase or decrease in focus-forming activity of these traptamers (Fig. S4), and all tagged traptamers induced tyrosine phosphorylation of the PDGFβR (Fig. 2E, third row). Detergent extracts of transformed BaF3 cells expressing βαβ traptamers were precipitated with anti-FLAG antibody and subjected to immunoblotting. The anti-FLAG antibody detected a ~8.5-kDa band in cells transduced with a FLAG-tagged traptamer gene (Fig. 2E, second row), confirming that the tagged traptamers were expressed.

Immunoblotting with anti-PDGFβR showed that anti-FLAG communoprecipitated the mature and precursor PDGFβR from cells expressing the FLAG-tagged traptamers, but not from cells expressing their untagged counterparts, indicating that the traptamers were present in a stable complex with the PDGFβR (Fig. 2E, Top). We further showed that the defective LI-5 isoleucine 13 to leucine mutant (see next paragraph) as well as two unselected traptamers associated poorly with the PDGFβR in a communoprecipitation experiment in comparison with the active traptamers, LI-5 and LI-7 (Fig. 2F). Furthermore, LI-5 and LI-7, which showed the most robust communoprecipitation with wild-type PDGFβR, failed to communoprecipitate with the βαβ receptor chimera, which contains an ectopic transmembrane domain and fails to cooperate with these traptamers in the BaF3 cell growth factor independence assay (Fig. 2F). This experiment shows that stable complex formation between the active traptamers and the PDGFβR correlates with transforming activity and requires the transmembrane domain of the receptor.

To determine if specific amino acids in the traptamers were required for activity, we conducted complete mutagenesis of LI-5 and LI-11, in which each leucine was changed individually to isoleucine and vice versa. Mutations at several positions dra-
matically inhibited focus formation (Fig. S5). LI-11 required isoleucines at positions 8, 13, and 22 and leucines at positions 2, 6, 14, 17, 20, 21, and 25 for high focus-forming activity (Fig. 3A). Leucine or isoleucine, as appropriate, was enriched at these positions in the active traptamers compared with the unselected traptamers (Fig. S6). LI-5 required a subset of these residues, L6, L13, L14, L17, and L21 (Fig. 3B). Thus, the requirements for LI-5 and LI-11 were similar but not identical. These mutagenesis results are summarized in Fig. 3C. Interestingly, none of the amino acids that differ between the two traptamers (shown in green in Fig. 3C) are required for activity. We then mutated the required isoleucines in LI-5 and LI-11 to valine, another hydrophobic amino acid (Fig. 4A). Substitution of a valine at position 13 abolished or severely inhibited the activity of both traptamers, but valine was tolerated at position 8 or 22 in LI-11 (Fig. 3D). These data suggest that isoleucine 13 is particularly important for traptamer activity and that the required isoleucines at positions 8 and 22 in LI-11 play a qualitatively different role than isoleucine 13 in transforming activity.

To ask if the inactivating mutations are likely to cause global disruption of traptamer structure, we used all-atom molecular dynamics simulations in explicit POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) lipid bilayers in excess water to generate models of wild-type LI-11 and its defective mutants, 11-I13L and 11-I13V (see SI Materials and Methods for the modeling and references). After initial equilibration, the simulations were run for 150 ns. The models of all three traptamers converged on stable, extended α-helical backbone structures roughly perpendicular to the lipid bilayer (tilt \(\sim 10^\circ\) to 25°), with position 13 in the middle of the bilayer (Fig. 3E). Notably, the backbone models of wild-type LI-11 and its two mutants were very similar (the average peptide backbone RMSD of wild-type LI-11 compared with either mutant was <1.7 Å). As expected for an α-helix, the radially displayed amino acid side-chains did not interact with each other or with the hydrophilic groups in the protein backbone and the arrangement of side-chain carbon atoms at position 13 in wild-type LI-11 was markedly different from their arrangement in the mutants (Fig. S7). These results imply that the inactivating amino acid substitutions at position 13 do not cause global alterations in the structure of the protein, but rather cause a local structural perturbation at the site of the mutation.

---

**Fig. 3.** Comprehensive mutational analysis of traptamers. (A) C127 cells were infected with low-titer retrovirus expressing the E5 protein, wild-type LI-11, or an LI-11 mutant in which a leucine was changed to isoleucine or an isoleucine was changed to leucine. Sequence of wild-type LI-11 starting at position 2 is shown at the bottom, with isoleucines shown in red and positions that differ between LI-5 and LI-11 highlighted in green. The bars above the sequence show the activity of the mutant with the substitution at that position. Transformed foci were counted after infected cells were incubated at confluence for 3 wk. Focus-forming activity displayed as in Fig. 1E. (B) Focus-forming activity of LI-5 mutants tested and displayed as in A. (C) Sequences of LI-5 and LI-11 are displayed as described in A. Residues that when mutated to leucine or isoleucine result in 80% or greater reduction in focus-forming activity are shown in boxes. (D) Focus-forming activity was measured and displayed as described in A for traptamers containing isoleucine (black), leucine (dark gray), or valine (light gray) at the indicated position in traptamer LI-11 (Left) or at position 13 in LI-5 (Right). (E) Molecular dynamics simulation indicates that the helical backbones of LI-11, LI-11-I13L, and LI-11-I13V are very similar. The diagram shows an overlay of lateral views of the backbones of three aligned helices. The horizontal dashed lines represent the approximate extent of the membrane bilayer hydrophobic region; the amino termini of the proteins are at the top.
Previous work in other laboratories showed that insertion of defined dimerization motifs was sufficient to drive homodimerization of transmembrane peptides (33–35). Because our results suggested that the mutations interfere with the transforming activity of the traptamers by acting locally on the structure of the traptamer, we tested whether introduction of isoleucines at crucial positions in a simple sequence was sufficient for biological activity. We inserted isoleucines into polyL25 at positions 8, 13, and 22 singly and in combination and tested the ability of these mutants to transform cells (Fig. 4A). All polyL25 mutants containing isoleucine at position 13 displayed focus-forming activity, whereas mutants lacking Ile13 were inactive, as was polyL25 containing valines at positions 8, 13, and 22 (Fig. 4B and Fig. S8). Most strikingly, polyL25 containing a single isoleucine at position 13 (polyL25-113) induced focus formation and morphologic transformation (Fig. 4 B and C and Fig. S9). Moreover, polyL25-18,13,22, and polyL25-113 induced specific tyrosine phosphorylation of the PDGFRβ in transformed HFFs (Fig. 4 D and E). We also constructed polyL25 mutants containing a single isoleucine at positions 11 through 15 and scored their ability to induce morphologic transformation and focus formation in C127 cells. Although isoleucine at position 13 conferred activity, mutants with an isoleucine at other positions were defective in these assays, demonstrating that the position of the isoleucine was important for transforming activity (Fig. 4B and Fig. S9). We also constructed FLAG-tagged versions of these traptamers and tested their activity in C127 cells. As expected, the isoleucine at position 13 conferred relatively high focus-forming activity (Fig. 4F). In addition, an isoleucine at flanking position 12 or 14 conferred ~10-fold lower activity, whereas traptamers with isoleucine at position 11 or 15 were inactive (Fig. 4F), even though all traptamers were expressed at similar levels (Fig. 4G). Thus, insertion of a single isoleucine at a particular position in a stretch of leucines is sufficient to specifically activate the PDGFRβ and transform cells, and isoleucine at an immediately adjacent position conferred weak transforming activity.

Discussion

We have used a genetic selection to isolate exceptionally simple 26-amino acid proteins with specific biological activity. Remarkably, these proteins contain only leucine and isoleucine and apparently a single transmembrane helix. Leucine and isoleucine side-chains differ only in the position of a methyl group, lack chemically reactive groups, and are not subject to posttranslational modification. Despite their chemical simplicity, these proteins specifically activate the endogenous PDGFRβ but no other receptors in transformed cells, and they confer growth factor independence in cooperation with wild-type PDGFRβ but not with other receptors or mutant PDGFRβs containing substitutions in the transmembrane region. In addition, conservative amino acid substitutions at specific positions in the traptamers inhibit activity without affecting the overall structure of the helix, and repositioning a single side-chain methyl group at position 13 from the γ-carbon to the β-carbon (thereby converting leucine to isoleucine)—but not at other positions—in an otherwise monotonous inactive protein is sufficient to generate biological activity.

Our results strongly suggest that traptamers consisting of only leucine and isoleucine can induce cell transformation by selectively interacting in a sequence-specific manner with the transmembrane domain of a cellular protein, most likely the PDGFRβ itself, resulting in specific activation of the receptor. Indeed, we showed that the active traptamers but not a defective mutant are present in a stable complex with the wild-type PDGFRβ but not with a chimeric PDGFRβ containing a foreign transmembrane domain. The specificity of the traptamers suggests that they are unlikely to transform cells by forming aggregates that cause non-specific receptor clustering. Thus, they differ from repeat-associated non-ATG (RAN) translation products, simple naturally occurring proteins translated in multiple reading frames from trinucleotide or hexanucleotide gene expansions, which cause neurologic disease by nonspecific aggregation and induction of cell toxicity (36). Determining how traptamers with such a limited chemical repertoire specifically recognize a target transmembrane domain will provide new insights into the structural basis for protein–protein recognition. Because leucine and isoleucine side-chains can participate in packing interactions only, further study of these traptamers will provide a focused view of this important class of interactions in the absence of alternative binding solutions provided by chemically diverse side-chains.

These short, simple proteins can be subjected to a level of mutational analysis that would be difficult if not impossible with conventional proteins. A leucine at certain positions in traptamers LI-5 and LI-11 is required for activity, and an isoleucine is required at certain other positions. Whether or not an amino acid is required at a particular position is determined in part by its context. For example, the isoleucines at position 8 and 22 are required in LI-11 but not in LI-5, even though both traptamers contain isoleucine at these positions. Interestingly, none of the positions that differ between LI-5 and LI-11 are required for high activity of either traptamer (Fig. 3C). Thus, the amino acids at nonessential positions can dictate whether an amino acid at a shared position is required for optimal activity, presumably by affecting the packing of the helices.

Our mutational analysis also indicated that not all required amino acids are equivalent: the isoleucines at position 8 and 22 in LI-11 cannot be replaced by leucine but can be replaced by valine, which like isoleucine is a β-branched amino acid, suggesting that rotational restriction of a β-branched side-chain at these positions, rather than the isoleucine side-chain per se, is important for LI-11 activity. In contrast, the isoleucine at position 13 in LI-5 and LI-11 cannot be replaced with valine or leucine without loss of activity, implying that the isoleucine side-chain at position 13 makes specific packing contacts essential for transforming activity. The very similar structures of valine, leucine, and isoleucine imply that the terminal methyl group of Ile13 makes an essential packing contact that is missing from the valine mutant. Furthermore, the second terminal methyl group in leucine may sterically clash with its binding partner, or an essential methyl group on the β-carbon may be missing in the leucine mutant.

The modification of a single isoleucine can have dramatic effects on transmembrane domain interactions. For example, a leucine to isoleucine mutation at position 512 in the transmembrane domain of the PDGFRβ disrupts the direct interaction between the PDGFRβ and the E5 protein, preventing transformation (17). Binding energy contributions from contacts at transmembrane helical interfaces have been measured, for example by Fleming et al. (37), who studied the homodimeric interaction of the GlycoporphinA transmembrane domain. This study showed the free energy of dissociation of the wild-type dimer is 9 kcal/mol, and that the disruptive L75A and I76A substitutions decrease affinity by 1.1 kcal/mol and 1.7 kcal/mol, respectively. These changes were attributed to changes in van der Waals interactions between the helices. Although it has been suggested that these energies, measured with peptides in detergent micelles, overestimate estimates in membranes (38), a change of only ~1.3 kcal/mol is sufficient to change a “strong” to a “weakly associated” transmembrane dimer (33), probably as a result of constraints imposed by the helical conformation in the lipid bilayer. The limited rotation of isoleucine compared with leucine may make an additional, entropic contribution to binding energy.

It is remarkable that polyL25 is activated by isoleucine at position 13, activated poorly by isoleucine at position 12 or 14, and not activated by isoleucine at position 11 or 15, because in all cases the single isoleucine is embedded in a long stretch of leucines. Thus, an isoleucine near the middle of the lipid bilayer is required for traptamer activity, and activity drops the farther the isoleucine is from this central position. The match between...
the hydrophobic profile of the helix and the hydrophobic profile of the membrane stabilizes the position of a transmembrane helix across a membrane with respect to the displacement of the helix perpendicular to the plane of the membrane. The pattern of activity of the polyL25 add-back traptamers implies that there is a permitted range of helix displacements across the membrane. A displacement from the free-energy minimum will cost energy, and when the displacement energy exceeds the energy of binding of the critical isoleucine with its target, the productive interaction will be lost. We speculate that the isoleucine side-chain at position 13 makes an essential packing contact with the hydrophilic threonine residue at position 513 in the middle of the PDGFβR transmembrane domain, a residue that is required for traptamer activity (Fig. 2D) and is proposed to interact directly with Gln17 of the E5 protein (21). Alternatively, these traptamers may act as homodimers, and Ile13 may allow the self-association of two molecules of the traptamer to generate an active dimer.

Our results demonstrate that proteins consisting of only two different amino acids can display specific biological activity. This
The UDv6 library was constructed by using receptor reveal a IL-3 Independence Assay. 8o f9 expression vector and transformed into DH10 cation, the amplification products were ligated into pMSCVpuro retroviral and T were used in the third position. After primer extension and amplification, the amplification products were ligated into pMSCVpuro retroviral expression vector and transformed into DH101 Escherichia coli. Plasmid DNA was harvested from ~5,500,000 pooled ampicillin-resistant colonies. Further details are in SI Materials and Methods.

Materials and Methods
Detailed experimental methods are presented in SI Materials and Methods.

Retroviral Library Construction. The UDv6 library was constructed by using degenerate oligonucleotides containing library-specific primer binding sites for amplification, a methionine start codon, and 25 degenerate codons encoding equimolar leucine and isoleucine followed by stop codons. To synthesize the randomized segment, equimolar A and C were used in the first position of each codon, T was used in the second position, and equimolar A, C, and T were used in the third position. After primer extension and amplification, the amplification products were ligated into pMSCVpuro retroviral expression vector and transformed into DH101 Escherichia coli. Plasmid DNA was harvested from ~5,500,000 pooled ampicillin-resistant colonies. Further details are in SI Materials and Methods.

IL-3 Independence Assay. BaF3 lines stably expressing a receptor were generated by infecting BaF3 cells with retrovirus containing a receptor gene cloned in the pLXSN retroviral vector and selection for G418 resistance. The resulting stable cell lines were infected with empty MSCVpuro, or MSCVpuro expressing a traptamer, E5 or v-sis, and selected with puromycin. To assay for IL-3 independent proliferation, washed cells were incubated in RPMI lacking IL-3. Some samples expressing EpoR or c-kit were treated with human erythropoietin or human stem cell factor, respectively. Further details are in SI Materials and Methods.

RTK Array. HFFs were infected with MSCV empty vector or viruses expressing a traptamer and selected in puromycin. Cells were serum-starved overnight before harvest. Some control samples were incubated with PDGF-DD or with a mixture of growth factors consisting of PDGF-BB, epidermal growth factor, fibroblast growth factor, nerve growth factor, and insulin in 50% (vol/vol) FBS before lysis. All subsequence steps were performed as described in the Human Phospho-RTK Array Kit (Proteome Profiler, R&D Systems). Briefly, the cells were lysed in the provided lysis buffer with protease and phosphatase inhibitors, then incubated with the nitrocellulose membranes overnight. Membranes were then incubated with the anti- Phospho-Tyrosine-HRP detection antibody and visualized with Chemi Agent Mix. Further details are in SI Materials and Methods.

Cloning, Tissue Culture, and Biochemical Analysis. Standard procedures were used for tissue culture, retrovirus production, cloning, immunoprecipitation, and immunoblotting. See SI Materials and Methods for details.

ACKNOWLEDGMENTS. We thank Emily Cohen and Kelly Chacon for helpful discussions; the Douglas Tobias (University of California, Irvine) group for guidance with the Molecular Dynamics simulations; and Jan Zulevski for assistance in preparing this manuscript. This study was supported in part by National Institutes of Health training Grants T32GM007499 (to E.N.H.) and T32GM007223 (to R.S.F.); National Institutes of Health Grants CA037175 (to D.D.) and GM073857 (to D.M.E.); and by generous gifts from Ms. Laurel Schwartz (to D.D.). Computational modeling used the Extreme Science and Engineering Discovery Environment was supported by National Science Foundation Grant ACI-1053575 (to D.M.E.).


